SF 552 — Anti-Obesity Medication Review and Report (Health and Human Services)
Overview
- Purpose: Requires the Department of Health and Human Services (HHS) and the Department of Administrative Services (DAS) to review anti-obesity medications, including GLP-1 agonists, for purposes of the medical assistance program (Medicaid) and health insurance plans for state employees.
- Goal: Assess effectiveness for weight loss, impact on obesity-related comorbidities, potential cost savings, eligibility considerations, and the costs of coverage.
Key Provisions
- Joint Review: HHS and DAS must jointly evaluate anti-obesity medications across two systems:
- Medicaid program (medical assistance) under chapter 249A
- State employee health insurance plans established under chapter 509A
- Evaluation Criteria:
- Effectiveness in promoting weight loss
- Impact on obesity-related comorbidities
- Potential cost savings from deferred medical procedures and reduced medications related to comorbidity
- Recommended eligibility requirements for coverage
- Short-term and long-term costs associated with coverage
- Any additional criteria the departments deem relevant
- Reporting Obligation: The departments must submit a joint report to the General Assembly by January 5, 2026. The report should include:
- Findings from the review
- Proposed eligibility requirements
- Short-term and long-term cost estimates associated with coverage
Scope and Definitions
- Medications Covered: Anti-obesity medications, including GLP-1 agonists, within the scope of the Medicaid program and state employee health plans.
- Programs Affected:
- Medical Assistance Program (Medicaid) under chapter 249A
- State employee health insurance plans under chapter 509A
Procedural and Timeline Details
- Introduction and Status:
- Introduced March 6, 2025
- Placed on calendar upon introduction; committee report approved
- Referred to Health and Human Services on June 16, 2025
- Reporting Deadline: January 5, 2026 for the joint report and proposed eligibility and cost information
Potential Impact and Considerations
- Policy Impact: Could influence future coverage decisions for anti-obesity medications within Medicaid and state employee plans, including eligibility standards and reimbursement policies.
- Fiscal Considerations: The bill contemplates analysis of both short-term and long-term costs and potential savings, which could affect state budgeting and plan design.
- Data and Stakeholders: Requires coordination between HHS and DAS, with consideration of health outcomes and economic implications for state programs and employees.
Status
- As of the latest actions, SF 552 has been referred to Health and Human Services, with a scheduled reporting requirement to the General Assembly by January 5, 2026.
